MRK · Company research
Merck & Co., Inc. (MRK): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
76records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Catholic Medical Mission Board and Church of the Brethren to mark partnership with ribbon-cutting | Catholic Medical Mission Board (CMMB) opened its new Distribution Center at the Brethren Service Center in New Windsor, Maryland on October 22, 2026. The relocation expands CMMB's operational capacity for its Access to Medicines Program, which distributed $243.5 million worth of medicines and medical supplies to 64 partners across 28 countries in 2025. The partnership strengthens both organizations' humanitarian efforts. | View source ↗ | GlobeNewswire Inc. | Oct 20, 2026 | bullish | 1 | 1 |
| GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth | GSK is focusing on newer specialty medicines and vaccines to offset pressure from older products and drive long-term growth. Recent product launches including Blenrep, Jemperli, and Arexvy are expected to become major revenue contributors, with Blenrep anticipated as a key growth driver over 3-4 years. The company has doubled its phase II and III blockbuster-potential assets since 2022 and expects sales exceeding £40 billion by 2031. However, GSK faces significant competition from major pharmaceutical companies and must navigate patent expirations, particularly in HIV. | View source ↗ | Zacks Investment Research | Oct 20, 2026 | neutral | 0.111 | 1 |
| Merck (MRK) Stock Dips While Market Gains: Key Facts | Merck (MRK) closed at $143.63, down 1.59% from the previous session, underperforming the S&P 500's 0.41% gain. The pharmaceutical company faces declining earnings expectations with Q3 EPS projected at $2.12 (down 17.83% YoY) and annual EPS forecast at $2.66 (down 70.38% YoY). With a Zacks Rank of #4 (Sell), a Forward P/E of 54.92 significantly above the industry average of 16.91, and a PEG ratio of 6.74 versus the industry average of 2.01, Merck appears overvalued. Consensus EPS estimates have fallen 3.83% over the past month. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bearish | -1 | 1 |
| Merck & Co., Inc. $MRK Stock: Birch Hill Investment Advisors LLC Cuts Holdings - MarketBeat | Merck & Co., Inc. $MRK Stock: Birch Hill Investment Advisors LLC Cuts Holdings MarketBeat | View source ↗ | MarketBeat | Oct 18, 2026 | neutral | 0 | 0.6 |
| Merck & Co., Inc. $MRK Stock: 1834 Investment Advisors Co. Decreases Position - MarketBeat | Merck & Co., Inc. $MRK Stock: 1834 Investment Advisors Co. Decreases Position MarketBeat | View source ↗ | MarketBeat | Oct 18, 2026 | neutral | 0 | 0.6 |
| Why Did MRNA, MRK, TGT Stocks Jump To 52-Week Highs Today? - Stocktwits | Why Did MRNA, MRK, TGT Stocks Jump To 52-Week Highs Today? Stocktwits | View source ↗ | Stocktwits | Oct 18, 2026 | neutral | 0 | 0.6 |
| Merck & Co., Inc. $MRK Stock: Hengehold Capital Management LLC Reduces Position - MarketBeat | Merck & Co., Inc. $MRK Stock: Hengehold Capital Management LLC Reduces Position MarketBeat | View source ↗ | MarketBeat | Oct 17, 2026 | neutral | 0 | 0.6 |
| Merck & Co., Inc. $MRK Stock: Cantor Fitzgerald Investment Advisors L.P. Cuts Position - MarketBeat | Merck & Co., Inc. $MRK Stock: Cantor Fitzgerald Investment Advisors L.P. Cuts Position MarketBeat | View source ↗ | MarketBeat | Oct 17, 2026 | neutral | 0 | 0.6 |
| Can Retail Earnings Keep S&P 500 Rally Alive? NLST, AVGO, LUNR, MRK Stocks In Focus - Stocktwits | Can Retail Earnings Keep S&P 500 Rally Alive? NLST, AVGO, LUNR, MRK Stocks In Focus Stocktwits | View source ↗ | Stocktwits | Oct 17, 2026 | neutral | 0 | 0.6 |
| Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? | The article compares Bristol-Myers Squibb and Johnson & Johnson as healthcare investment options. BMY trades at a cheaper valuation (9.3x forward P/E vs JNJ's 21x) with a higher dividend yield of 4.16%, but faces patent cliffs and pricing pressures. JNJ offers greater revenue scale ($94.2B vs $48.2B), diversified business segments, and a 64-year dividend growth streak, making it the recommended choice for 2026 despite its premium valuation. | View source ↗ | The Motley Fool | Oct 17, 2026 | bullish | 0.167 | 1 |
| Novo Nordisk and Eli Lilly Just Got Some Fantastic News | A NIH-funded study found that the GLP-1 drug semaglutide extended lifespan and slowed aging in older mice by improving muscle and cognitive function and reducing inflammation. The findings could accelerate adoption of GLP-1 drugs from Novo Nordisk and Eli Lilly, with forecasts predicting 25 million Americans on these treatments by 2030 and a market reaching $190 billion by 2035. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.667 | 1 |
| Novo Nordisk and Eli Lilly Just Got Some Fantastic News | A NIH-funded study found that the GLP-1 drug semaglutide extended lifespan and slowed aging in older mice by improving muscle and cognitive function and reducing inflammation. The findings could accelerate adoption of GLP-1 drugs from Novo Nordisk and Eli Lilly, with forecasts predicting 25 million Americans on these treatments by 2030 and a market reaching $190 billion by 2035. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.667 | 1 |
| Eli Lilly's Biggest Shareholder Is Selling $347 Million of Stock. Should You Sell Too? | The Lilly Foundation, Eli Lilly's largest shareholder with 9.6% ownership, is selling 300,000 shares worth $347 million. However, this sale is a required annual charity payout and does not reflect bearish sentiment on the stock. Eli Lilly is leading the GLP-1 drug revolution with its tirzepatide drug (Mounjaro/Zepbound) becoming the world's best-selling drug. With Morgan Stanley forecasting the GLP-1 market to reach $190 billion by 2035 and Wall Street analysts targeting 10% upside, the article recommends buying rather than selling. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.5 | 1 |
| Eli Lilly's Biggest Shareholder Is Selling $347 Million of Stock. Should You Sell Too? | The Lilly Foundation, Eli Lilly's largest shareholder with 9.6% ownership, is selling 300,000 shares worth $347 million. However, this sale is a required annual charity payout and does not reflect bearish sentiment on the stock. Eli Lilly is leading the GLP-1 drug revolution with its tirzepatide drug (Mounjaro/Zepbound) becoming the world's best-selling drug. With Morgan Stanley forecasting the GLP-1 market to reach $190 billion by 2035 and Wall Street analysts targeting 10% upside, the article recommends buying rather than selling. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.5 | 1 |
| Meet the New Nasdaq-100 Stock That’s Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy? | Moderna stock has surged over 600% in 2026, outperforming major AI stocks like Nvidia, Micron, and Sandisk, driven by progress in its oncology pipeline, particularly its personalized cancer vaccine candidate intismeran autogene. The stock now trades 61% above Wall Street's average price target of $122, and while the company shows promise as it transforms from a coronavirus vaccine company into a broader biotech player, the analyst recommends waiting for a pullback before buying. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.4 | 1 |
| Meet the New Nasdaq-100 Stock That’s Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy? | Moderna stock has surged over 600% in 2026, outperforming major AI stocks like Nvidia, Micron, and Sandisk, driven by progress in its oncology pipeline, particularly its personalized cancer vaccine candidate intismeran autogene. The stock now trades 61% above Wall Street's average price target of $122, and while the company shows promise as it transforms from a coronavirus vaccine company into a broader biotech player, the analyst recommends waiting for a pullback before buying. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.4 | 1 |
| Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock - Yahoo Finance | Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock | Merck (MRK) is trending but faces headwinds with a Zacks Rank #4 (Sell) rating. The company shows significant earnings estimate revisions downward, with current fiscal year earnings expected to decline 70.4% year-over-year, though next fiscal year projects a 248.6% recovery. Revenue growth remains modest at 3.2% for the current fiscal year. The stock has underperformed relative to the S&P 500 over the past month and is trading at par valuation with peers. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bearish | -1 | 1 |
| Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock | Merck (MRK) is trending but faces headwinds with a Zacks Rank #4 (Sell) rating. The company shows significant earnings estimate revisions downward, with current fiscal year earnings expected to decline 70.4% year-over-year, though next fiscal year projects a 248.6% recovery. Revenue growth remains modest at 3.2% for the current fiscal year. The stock has underperformed relative to the S&P 500 over the past month and is trading at par valuation with peers. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bearish | -1 | 1 |
| Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now? | The First Trust NASDAQ Pharmaceuticals ETF (FTXH) is a smart beta ETF with $1.07 billion in assets that tracks the Nasdaq US Smart Pharmaceuticals Index. With a 0.60% expense ratio and 51 holdings, it has delivered strong performance of 25.84% year-to-date and 43.75% over the past year as of October 15, 2026. However, investors should consider alternative pharmaceutical ETFs like VanEck Pharmaceutical ETF (PPH) and iShares U.S. Pharmaceuticals ETF (IHE), which offer lower expense ratios. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.5 | 1 |
| Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now? | The First Trust NASDAQ Pharmaceuticals ETF (FTXH) is a smart beta ETF with $1.07 billion in assets that tracks the Nasdaq US Smart Pharmaceuticals Index. With a 0.60% expense ratio and 51 holdings, it has delivered strong performance of 25.84% year-to-date and 43.75% over the past year as of October 15, 2026. However, investors should consider alternative pharmaceutical ETFs like VanEck Pharmaceutical ETF (PPH) and iShares U.S. Pharmaceuticals ETF (IHE), which offer lower expense ratios. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.5 | 1 |
| Why Did RUM, MRK, NEM Stocks Jump To 52-Week Highs Today? - Stocktwits | Why Did RUM, MRK, NEM Stocks Jump To 52-Week Highs Today? Stocktwits | View source ↗ | Stocktwits | Oct 14, 2026 | neutral | 0 | 0.6 |
| Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings? | Merck's blockbuster cancer drug Keytruda generated $16.40 billion in first-half 2026 sales, up 4.2% year-over-year, with expectations for continued growth through 2028 when it reaches peak sales of $35 billion. However, the company faces significant headwinds as biosimilar competition is expected around 2028-2029, which will likely cause sharp sales declines. Merck stock has outperformed the industry year-to-date but currently holds a Zacks Rank #4 (Sell) rating. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | neutral | 0 | 1 |
| Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings? | Merck's blockbuster cancer drug Keytruda generated $16.40 billion in first-half 2026 sales, up 4.2% year-over-year, with expectations for continued growth through 2028 when it reaches peak sales of $35 billion. However, the company faces significant headwinds as biosimilar competition is expected around 2028-2029, which will likely cause sharp sales declines. Merck stock has outperformed the industry year-to-date but currently holds a Zacks Rank #4 (Sell) rating. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | neutral | 0 | 1 |
| History Says This Is Hands-Down the Best ETF to Buy if a Bear Market Is Coming | With concerns about a potential bear market, the article recommends the Schwab U.S. Dividend Equity ETF (SCHD) as a defensive investment strategy. Based on 2022 bear market performance, defensive sectors like healthcare, consumer staples, and energy outperformed tech-heavy indexes. SCHD holds 102 stocks with minimal tech exposure (9.23%) and heavy weighting in defensive sectors, making it suitable for portfolio protection during economic downturns. | View source ↗ | The Motley Fool | Oct 14, 2026 | bullish | 1 | 1 |
| History Says This Is Hands-Down the Best ETF to Buy if a Bear Market Is Coming | With concerns about a potential bear market, the article recommends the Schwab U.S. Dividend Equity ETF (SCHD) as a defensive investment strategy. Based on 2022 bear market performance, defensive sectors like healthcare, consumer staples, and energy outperformed tech-heavy indexes. SCHD holds 102 stocks with minimal tech exposure (9.23%) and heavy weighting in defensive sectors, making it suitable for portfolio protection during economic downturns. | View source ↗ | The Motley Fool | Oct 14, 2026 | bullish | 1 | 1 |
| Merck (MRK) Dips More Than Broader Market: What You Should Know | Merck (MRK) closed down 2.39% and underperformed the S&P 500. The pharmaceutical company faces declining earnings projections with consensus estimates showing a 17.83% year-over-year EPS decline for the upcoming quarter and a 70.38% decline for the full fiscal year. The stock carries a Zacks Rank of #4 (Sell) with a Forward P/E ratio of 54.73, significantly above the industry average of 16.15. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bearish | -1 | 1 |
| Merck (MRK) Reports a Negative Operating Margin and Pays Out 266% of Earnings. What Explains Both? - Yahoo Finance | Merck (MRK) Reports a Negative Operating Margin and Pays Out 266% of Earnings. What Explains Both? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 13, 2026 | neutral | 0 | 0.6 |
| Merck (MRK) Stock Could Be A Bargain As Its 120% Run Continues - Simply Wall Street | Merck (MRK) Stock Could Be A Bargain As Its 120% Run Continues Simply Wall Street | View source ↗ | Simply Wall Street | Oct 13, 2026 | neutral | 0 | 0.6 |
| MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell? | Moderna's stock gained over 5% in a week, adding $4.2 billion in market value, driven by positive phase III melanoma results for its cancer therapy intismeran and inclusion in the Nasdaq-100 Index. While the company shows promise in oncology and respiratory vaccines, its 625% YTD rally has resulted in a premium valuation that leaves it vulnerable to disappointment. The stock is rated a Hold, with short-term investors advised to book profits while long-term investors may consider holding for future growth opportunities. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.2 | 1 |
| MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell? | Moderna's stock gained over 5% in a week, adding $4.2 billion in market value, driven by positive phase III melanoma results for its cancer therapy intismeran and inclusion in the Nasdaq-100 Index. While the company shows promise in oncology and respiratory vaccines, its 625% YTD rally has resulted in a premium valuation that leaves it vulnerable to disappointment. The stock is rated a Hold, with short-term investors advised to book profits while long-term investors may consider holding for future growth opportunities. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.2 | 1 |
| Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? | The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline. Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential. | View source ↗ | The Motley Fool | Oct 13, 2026 | neutral | 0.143 | 1 |
| Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? | The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline. Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential. | View source ↗ | The Motley Fool | Oct 13, 2026 | neutral | 0.143 | 1 |
| Johnson & Johnson (JNJ) Q3 Earnings Surpass Estimates | Johnson & Johnson reported Q3 2026 earnings of $2.59 per share, beating consensus estimates of $2.53, though revenues slightly missed expectations at $25.4 billion. Despite outperforming the S&P 500 by 27.4% year-to-date, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends, suggesting near-term underperformance. The Large Cap Pharmaceuticals industry ranks in the bottom 16% of sectors. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bearish | -1 | 1 |
| Johnson & Johnson (JNJ) Q3 Earnings Surpass Estimates | Johnson & Johnson reported Q3 2026 earnings of $2.59 per share, beating consensus estimates of $2.53, though revenues slightly missed expectations at $25.4 billion. Despite outperforming the S&P 500 by 27.4% year-to-date, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends, suggesting near-term underperformance. The Large Cap Pharmaceuticals industry ranks in the bottom 16% of sectors. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bearish | -1 | 1 |
| BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock? | Bristol Myers Squibb (BMY) has outperformed the S&P 500 with a 35.8% gain over the past year, driven by strong performance from its Growth Portfolio including Opdivo Qvantig, Reblozyl, Camzyos, and Breyanzi. Recent FDA approvals like Zenbexus and positive pipeline progress offer long-term growth potential. However, the legacy portfolio faces continued generic competition, and much of the near-term optimism appears reflected in current valuations. Analysts recommend a cautious stance with a Hold rating. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | neutral | 0 | 1 |
| Tempus AI Expands Strategic Collaborations to Drive Future Growth | Tempus AI (TEM) is strengthening its precision medicine presence through multiple strategic collaborations, including support for Moderna and Merck's cancer therapy commercialization and an extended data partnership with Recursion Pharmaceuticals through 2029. However, TEM's stock has underperformed the industry by 30.6% over the past year and trades at a premium valuation of 6.73X forward P/S versus the industry average of 4.90X, with the stock currently rated a Hold. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 0.833 | 1 |
| Merck & Co., Inc. (NYSE:MRK) Stock Price Target Cut by Royal Bank Of Canada - MarketBeat | Merck & Co., Inc. (NYSE:MRK) Stock Price Target Cut by Royal Bank Of Canada MarketBeat | View source ↗ | MarketBeat | Oct 12, 2026 | neutral | 0 | 0.6 |
| Merck & Company, Inc. (MRK) Stock Forecasts - Yahoo Finance | Merck & Company, Inc. (MRK) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 12, 2026 | neutral | 0 | 0.6 |
| Why Did ROKU, MRK, SCHW Stocks Jump To 52-Week Highs? - Stocktwits | Why Did ROKU, MRK, SCHW Stocks Jump To 52-Week Highs? Stocktwits | View source ↗ | Stocktwits | Oct 12, 2026 | neutral | 0 | 0.6 |
| Merck's eye drug met the vision benchmark, but eye complications were more frequent - Stock Titan | Merck's eye drug met the vision benchmark, but eye complications were more frequent Stock Titan | View source ↗ | Stock Titan | Oct 10, 2026 | neutral | 0 | 0.6 |
| MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership - Stocktwits | MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership Stocktwits | View source ↗ | Stocktwits | Oct 10, 2026 | neutral | 0 | 0.6 |
| Merck (MRK) Stock Trades Below Fair Value Despite Its 117% Run - Yahoo Finance | Merck (MRK) Stock Trades Below Fair Value Despite Its 117% Run Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| Does The Move In Merck Stock Change Anything? - Trefis | Does The Move In Merck Stock Change Anything? Trefis | View source ↗ | Trefis | Oct 9, 2026 | neutral | 0 | 0.6 |
| HALO Wins Court Order Blocking Merck's Keytruda SC in Europe | A Dutch patent court ruled that Merck's Keytruda subcutaneous formulation infringes Halozyme's MDASE patent, ordering Merck to cease manufacturing and sales across eight European markets. The ruling does not affect Keytruda's intravenous version. This marks another legal victory for Halozyme against Merck, though the company clarified that its separate ENHANZE technology and licensing business remain unaffected. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| HALO Wins Court Order Blocking Merck's Keytruda SC in Europe | A Dutch patent court ruled that Merck's Keytruda subcutaneous formulation infringes Halozyme's MDASE patent, ordering Merck to cease manufacturing and sales across eight European markets. The ruling does not affect Keytruda's intravenous version. This marks another legal victory for Halozyme against Merck, though the company clarified that its separate ENHANZE technology and licensing business remain unaffected. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| HALO Wins Court Order Blocking Merck's Keytruda SC in Europe | A Dutch patent court ruled that Merck's Keytruda subcutaneous formulation infringes Halozyme's MDASE patent, ordering Merck to cease manufacturing and sales across eight European markets. The ruling does not affect Keytruda's intravenous version. This marks another legal victory for Halozyme against Merck, though the company clarified that its separate ENHANZE technology and licensing business remain unaffected. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results | Pfizer's oncology revenues rose 3% to $4.17 billion in Q2 2026, representing 27% of total revenues. The company expects Q3 growth driven by newer drugs like Padcev, Lorbrena, and Braftovi-Mektovi, offset by declines in Ibrance and Adcetris. Pfizer is advancing the dual PD-1/VEGF inhibitor PF-08634404 across nine studies including two pivotal phase III trials. The stock trades at an attractive valuation with a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.667 | 1 |
| Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results | Pfizer's oncology revenues rose 3% to $4.17 billion in Q2 2026, representing 27% of total revenues. The company expects Q3 growth driven by newer drugs like Padcev, Lorbrena, and Braftovi-Mektovi, offset by declines in Ibrance and Adcetris. Pfizer is advancing the dual PD-1/VEGF inhibitor PF-08634404 across nine studies including two pivotal phase III trials. The stock trades at an attractive valuation with a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.667 | 1 |
| Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results | Pfizer's oncology revenues rose 3% to $4.17 billion in Q2 2026, representing 27% of total revenues. The company expects Q3 growth driven by newer drugs like Padcev, Lorbrena, and Braftovi-Mektovi, offset by declines in Ibrance and Adcetris. Pfizer is advancing the dual PD-1/VEGF inhibitor PF-08634404 across nine studies including two pivotal phase III trials. The stock trades at an attractive valuation with a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.667 | 1 |
| INVA vs. MRK: Which Stock Is the Better Value Option? | In a comparison of two large cap pharmaceutical stocks, Innoviva (INVA) emerges as the superior value option compared to Merck (MRK). INVA holds a Zacks Rank of #2 (Buy) versus MRK's #3 (Hold), and demonstrates significantly better valuation metrics including a forward P/E of 9.12 versus MRK's 53.42, a PEG ratio of 3.04 versus 6.42, and a P/B ratio of 1.24 versus 8.4. INVA received a Value grade of A while MRK received a C. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.5 | 1 |
| INVA vs. MRK: Which Stock Is the Better Value Option? | In a comparison of two large cap pharmaceutical stocks, Innoviva (INVA) emerges as the superior value option compared to Merck (MRK). INVA holds a Zacks Rank of #2 (Buy) versus MRK's #3 (Hold), and demonstrates significantly better valuation metrics including a forward P/E of 9.12 versus MRK's 53.42, a PEG ratio of 3.04 versus 6.42, and a P/B ratio of 1.24 versus 8.4. INVA received a Value grade of A while MRK received a C. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.5 | 1 |
| INVA vs. MRK: Which Stock Is the Better Value Option? | In a comparison of two large cap pharmaceutical stocks, Innoviva (INVA) emerges as the superior value option compared to Merck (MRK). INVA holds a Zacks Rank of #2 (Buy) versus MRK's #3 (Hold), and demonstrates significantly better valuation metrics including a forward P/E of 9.12 versus MRK's 53.42, a PEG ratio of 3.04 versus 6.42, and a P/B ratio of 1.24 versus 8.4. INVA received a Value grade of A while MRK received a C. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.5 | 1 |
| Merck & Co., Inc. (NYSE:MRK) Stock Price Target Raised at Cantor Fitzgerald - MarketBeat | Merck & Co., Inc. (NYSE:MRK) Stock Price Target Raised at Cantor Fitzgerald MarketBeat | View source ↗ | MarketBeat | Oct 8, 2026 | neutral | 0 | 0.6 |
| Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock? | Moderna (MRNA) will be added to the Nasdaq-100 Index on October 9, replacing Warner Bros. Discovery following its acquisition by Paramount. The inclusion comes after Moderna's 566% year-to-date stock surge and positive phase III results for its personalized cancer therapy developed with Merck. While the index addition could drive incremental institutional demand through index-tracking funds managing over $800 billion in assets, it does not change the company's underlying fundamentals. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.5 | 1 |
| Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock? | Moderna (MRNA) will be added to the Nasdaq-100 Index on October 9, replacing Warner Bros. Discovery following its acquisition by Paramount. The inclusion comes after Moderna's 566% year-to-date stock surge and positive phase III results for its personalized cancer therapy developed with Merck. While the index addition could drive incremental institutional demand through index-tracking funds managing over $800 billion in assets, it does not change the company's underlying fundamentals. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.5 | 1 |
| How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings? | Eli Lilly's oncology segment is projected to generate $2.65 billion in Q3 2026 revenues, with growth driven by newer drugs like Jaypirca, Retevmo, and Inluriyo offsetting slower Verzenio sales. The company faces intense competition from AstraZeneca, Merck, and Pfizer in the oncology space. LLY stock has risen 10.6% year-to-date but trades at a premium valuation of 26.80x forward earnings. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.75 | 1 |
| How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings? | Eli Lilly's oncology segment is projected to generate $2.65 billion in Q3 2026 revenues, with growth driven by newer drugs like Jaypirca, Retevmo, and Inluriyo offsetting slower Verzenio sales. The company faces intense competition from AstraZeneca, Merck, and Pfizer in the oncology space. LLY stock has risen 10.6% year-to-date but trades at a premium valuation of 26.80x forward earnings. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.75 | 1 |
| Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now? | The American Century U.S. Quality Value ETF (VALQ) is reviewed as a reasonable smart beta option for investors seeking value exposure with broad diversification across 226 holdings. The fund has delivered 7.02% returns year-to-date and 10.23% over the past year, with a competitive 0.29% expense ratio. However, cheaper alternatives like iShares Core S&P U.S. Value ETF (IUSV) at 0.04% expense ratio and traditional market cap-weighted ETFs may be better for cost-conscious investors. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.286 | 1 |
| Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now? | The American Century U.S. Quality Value ETF (VALQ) is reviewed as a reasonable smart beta option for investors seeking value exposure with broad diversification across 226 holdings. The fund has delivered 7.02% returns year-to-date and 10.23% over the past year, with a competitive 0.29% expense ratio. However, cheaper alternatives like iShares Core S&P U.S. Value ETF (IUSV) at 0.04% expense ratio and traditional market cap-weighted ETFs may be better for cost-conscious investors. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.286 | 1 |
| Merck & Co., Inc. (NYSE:MRK) Stock Price Target Lowered at Morgan Stanley - MarketBeat | Merck & Co., Inc. (NYSE:MRK) Stock Price Target Lowered at Morgan Stanley MarketBeat | View source ↗ | MarketBeat | Oct 7, 2026 | neutral | 0 | 0.6 |
| Merck (MRK) Beats Stock Market Upswing: What Investors Need to Know | Merck (MRK) closed at $141.94, up 1.72%, outperforming the S&P 500's 0.58% gain. The pharmaceutical company is set to report earnings on October 29, 2026, with forecasted EPS of $2.25 (down 12.79% YoY) and revenue of $17.52 billion (up 1.39% YoY). MRK holds a Zacks Rank #3 (Hold) with a Forward P/E of 50.47, significantly above the industry average of 15.89. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | neutral | 0 | 1 |
| Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity? | Merck's stock declined 7.2% recently after a strong 60% annual gain, but analysts view this as a healthy pullback. While the company faces near-term headwinds including Gardasil weakness, generic competition, and Keytruda's 2028 patent expiration, its expanding pipeline with 20 new drug launches expected by 2030 and strategic acquisitions position it for long-term growth. The company maintains a Hold rating with potential as a buying opportunity for long-term investors. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.25 | 1 |
| Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity? | Merck's stock declined 7.2% recently after a strong 60% annual gain, but analysts view this as a healthy pullback. While the company faces near-term headwinds including Gardasil weakness, generic competition, and Keytruda's 2028 patent expiration, its expanding pipeline with 20 new drug launches expected by 2030 and strategic acquisitions position it for long-term growth. The company maintains a Hold rating with potential as a buying opportunity for long-term investors. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.25 | 1 |
| Merck Slides as Investors Weigh Recent Pipeline Setback Against Positive Drug Updates - Quiver Quantitative | Merck Slides as Investors Weigh Recent Pipeline Setback Against Positive Drug Updates Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 5, 2026 | neutral | 0 | 0.6 |
| Should You Invest in the VanEck Pharmaceutical ETF (PPH)? | The VanEck Pharmaceutical ETF (PPH) offers low-cost exposure to the healthcare-pharma sector with a 0.36% expense ratio and $1.01 billion in assets. The fund tracks the MVIS US Listed Pharmaceutical 25 Index and holds major pharmaceutical companies like Eli Lilly, Merck, and Novartis. With a Zacks ETF Rank of 3 (Hold), year-to-date gains of 6.51%, and a medium-risk profile, PPH is presented as a reasonable option for investors seeking diversified pharma exposure, though alternative ETFs like FTXH and IHE are also available. | View source ↗ | Zacks Investment Research | Oct 5, 2026 | bullish | 0.167 | 1 |
| Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP | VanEck Pharmaceutical ETF (PPH) offers lower costs (0.36% expense ratio) and higher dividend yield (2%), making it better for long-term buy-and-hold investors. Invesco Pharmaceuticals ETF (PJP) delivered stronger 1-year returns (41% vs 31%) with more balanced U.S.-focused holdings, but charges higher fees (0.58%) and offers lower yield (0.9%). | View source ↗ | The Motley Fool | Oct 3, 2026 | bullish | 0.25 | 1 |
| Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting | Evaxion will present new immune profiling data from its phase 2 trial of personalized cancer vaccine EVX-01 combined with pembrolizumab at the SITC 2026 Annual Meeting in November. The data will showcase systemic immunomodulatory effects beyond vaccine-specific T-cell responses. Previous two-year data showed a 75% objective response rate in advanced melanoma patients, with 92% still responding at two-year follow-up and no relapses observed. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bullish | 0.5 | 1 |
| Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting | Evaxion will present new immune profiling data from its phase 2 trial of personalized cancer vaccine EVX-01 combined with pembrolizumab at the SITC 2026 Annual Meeting in November. The data will showcase systemic immunomodulatory effects beyond vaccine-specific T-cell responses. Previous two-year data showed a 75% objective response rate in advanced melanoma patients, with 92% still responding at two-year follow-up and no relapses observed. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bullish | 0.5 | 1 |
| Merck (MRK) director receives 55.9149 stock-linked units, payable entirely in cash - Stock Titan | Merck (MRK) director receives 55.9149 stock-linked units, payable entirely in cash Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study | Merck announced that its investigational drug tulisokibart met the primary endpoint in a phase IIb study for moderate to severe hidradenitis suppurativa. High-dose and medium-dose regimens demonstrated superiority over placebo, with 72% and 64% of patients achieving HiSCR50 response respectively, compared to 35% for placebo. The drug also showed improvements in quality of life measures. Merck plans to advance tulisokibart into phase III development for HS and is evaluating it across six immune-mediated indications. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 0.25 | 1 |
| Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study | Merck announced that its investigational drug tulisokibart met the primary endpoint in a phase IIb study for moderate to severe hidradenitis suppurativa. High-dose and medium-dose regimens demonstrated superiority over placebo, with 72% and 64% of patients achieving HiSCR50 response respectively, compared to 35% for placebo. The drug also showed improvements in quality of life measures. Merck plans to advance tulisokibart into phase III development for HS and is evaluating it across six immune-mediated indications. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 0.25 | 1 |
| ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell? | AbbVie's stock has gained 25.4% over six months, driven by strong growth from Skyrizi and Rinvoq, which are expected to generate over $31 billion in combined 2026 sales. The company is successfully navigating Humira's patent expiry through new immunology and neuroscience products. However, challenges include Humira biosimilar erosion, slowing oncology sales, and weakness in the Aesthetics business. Analysts recommend holding the stock (Zacks Rank #3) as long-term prospects remain intact with expected 10% revenue growth in 2026. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 0.25 | 1 |
| ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell? | AbbVie's stock has gained 25.4% over six months, driven by strong growth from Skyrizi and Rinvoq, which are expected to generate over $31 billion in combined 2026 sales. The company is successfully navigating Humira's patent expiry through new immunology and neuroscience products. However, challenges include Humira biosimilar erosion, slowing oncology sales, and weakness in the Aesthetics business. Analysts recommend holding the stock (Zacks Rank #3) as long-term prospects remain intact with expected 10% revenue growth in 2026. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 0.25 | 1 |
| Why Merck (MRK) Dipped More Than Broader Market Today | Merck (MRK) declined 2.66% to $145.31, underperforming the S&P 500. The pharmaceutical company's upcoming Q3 2026 earnings are expected on October 29, with projected EPS of $2.25 (down 12.79% YoY) and revenue of $17.52 billion (up 1.39% YoY). The stock carries a Zacks Rank #3 (Hold) with a Forward P/E of 53.99, significantly above the industry average of 16.43. | View source ↗ | Zacks Investment Research | Sep 30, 2026 | bearish | -1 | 1 |
| Merck (MRK) Stock May Be 37% Undervalued On Fresh FDA Approval - Yahoo Finance | Merck (MRK) Stock May Be 37% Undervalued On Fresh FDA Approval Yahoo Finance | View source ↗ | Yahoo Finance | Sep 25, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.